| Today's Big NewsJan 11, 2023 |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
| By Angus Liu After GSK quickly pulled its accelerated approval for Blenrep after a confirmatory trial failure, FDA commissioner Robert Califf has weighed in on the state of the regulatory pathway. |
|
|
|
By Paige Minemyer Pharmacy benefit managers have touted the coming wave of biosimilar drugs as presenting a major opportunity to drive down drug prices, and Cigna, the parent company of Express Scripts, is no exception. |
By Andrea Park SAN FRANCISCO—"There’s nothing more fun than the chaos of success." Dexcom CEO Kevin Sayer discussed the worldwide launch of the newly FDA-cleared G7 glucose monitor with Fierce Medtech at the J.P. Morgan Healthcare Conference on Tuesday. |
By Max Bayer Ionis once had AstraZeneca involved and spied a bright future for the PCSK9 inhibitor ION449. But now, after the U.K. pharma backed out last year, CEO Brett Monia thinks the drug may have missed its shot. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Zoey Becker It's the moment of truth for AbbVie. The first Humira biosimilar is set to launch later this month, with many more to follow throughout the year. Despite the threats, the company is "well positioned" to absorb the blow, CEO Rick Gonzalez said at JPM. |
By Heather Landi SAN FRANCISCO—Ascension Health has charted a $2.5 billion economic recovery plan that executives say has helped the health system to weather ongoing operational challenges and staffing and inflationary pressures. |
By James Waldron Gilmore O’Neill has certainly made an impact in his first six months as CEO of Editas Medicine, culminating in a major pipeline clear out and 20% workforce layoffs this week. But judging by his JPM comments, we shouldn’t expect things to quieten down at Editas anytime soon. |
By Annalee Armstrong Annexon CEO Douglas Love said the company is giving itself "two ways to win” in the upcoming pivotal phase 2/3 trial for Huntington’s disease therapy ANX005, during remarks at the J.P. Morgan Healthcare Conference Wednesday morning. |
By Andrea Park,Conor Hale After years of stops, starts and stops again, the J.P. Morgan Healthcare Conference has returned to the city by the bay in full form. We've compiled the biggest medtech news so far, bite-sized. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong,James Waldron Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan Healthcare Conference. |
By Robert King New leaders of the pivotal House Ways and Means Committee and the House Energy and Commerce Committee are expected to be staunch advocates for the Medicare Advantage program and telehealth expansion. |
By Eric Sagonowsky As AstraZeneca fights to defend its aging two-drug inhaler Symbicort against generics, the company has a new approval to bolster its respiratory business. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
